# Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

> **NCT00602446** · PHASE2 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 4 (actual)

## Conditions studied

- Breast Cancer
- Iron Overload
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Neuroblastoma
- Ovarian Cancer

## Interventions

- **DRUG:** deferasirox

## Key facts

- **NCT ID:** NCT00602446
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2009-09
- **Final completion:** 2009-12
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Due to slow accrual of patients
- **Last updated:** 2017-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602446, "Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT00602446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*